Increasing prevalence of Non-Hodgkin lymphomas (NHL) and other types of cancers to drive global Non-Hodgkin Lymphoma (NHL) therapeutics market
According to TechSci Research report, “Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2026”, the market was valued at USD7931.54 million in 2020 and is expected to reach USD14689.31 million in 2026 by witnessing double digit CAGR of 10.02% during the forecast period. The global Non-Hodgkin Lymphoma (NHL) therapeutics market is primarily driven by growing prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancers around the world coupled with increasing expenditure on medical and healthcare infrastructure. Also, increasing awareness towards the effects of Non-Hodgkin’s lymphomas (NHL) and extensive R&D activities are acting as some other major drivers for this market. In addition to this, factors like the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs and increasing demand for innovative drugs and novel technologies are expected to drive the market growth through 2026.
Moreover, patent expiry of standard drugs, especially in untapped markets is anticipated to provide profitable growth opportunities for this market in near future. Apart from this, improved diagnostic techniques to detect NHL is fueling the growth of global Non-Hodgkin Lymphoma (NHL) therapeutics market. However, the market is also susceptible to some restraints. High cost of NHL drugs and stringent regulatory guidelines is anticipated to limit the market growth. Furthermore, various complications associated with NHL drugs are expected to hamper the global Non-Hodgkin Lymphoma (NHL) therapeutics market growth in coming years.
Browse 132 figures spread through 110 Pages and an in-depth TOC on “Global Non-Hodgkin Lymphoma Therapeutics Market”
https://www.techsciresearch.com/report/non-hodgkin-lymphoma-nhl-therapeutics-market/5113.html
The global Non-Hodgkin Lymphoma (NHL) therapeutic market is segmented based on type of therapy, cell type, drug type, distribution channel and region. Based on type of therapy, the market can be segmented into immunotherapy, targeted therapy, chemotherapy, stem cell transplant, others. Among these, immunotherapy segment dominated the market in 2020 and is further projected to maintain its dominance in the next 5 years as well. This can be attributed to higher revenue realization by these drugs. Targeted therapy is anticipated to register highest growth in the market over the coming years owing to high accuracy of these therapies in targeting cancer. In addition to this, presence of large number of targeted therapies for Non-Hodgkin Lymphoma (NHL) treatment is another factor which is further contributing to the high growth of this segment.
Regionally, North America dominated global Non-Hodgkin Lymphoma therapeutics market in 2020. High prevalence of Non-Hodgkin lymphoma (NHL) in the region and efforts by leading pharmaceutical companies to develop efficient treatment options is further expected to aid the market growth in North America during the forecast period. The second most dominating market is expected to be Europe on account of growing number of patients requiring treatment in the region and high usage of advanced therapeutics. However, Asia-Pacific is anticipated to undergo fastest growth through 2026 due to improving healthcare reimbursement policies and increasing prevalence of Non-Hodgkin lymphoma (NHL) among the population in the region.
Major players operating in the global Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc. The market is highly competitive and key market players are investing on R&D activities to introduce new and more effective products in global market.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5113
Customers can also request for 10% free customization on this report.
“Extensive R&D activities are the most important tool for the growth of Non-Hodgkin Lymphoma therapeutics market, which is why, large number of pharmaceutical companies are engaged in these activities to develop innovative formulations. Also, availability of the biosimilars at a reduced price is leading to high growth in global Non-Hodgkin Lymphoma (NHL) therapeutics market,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2026”has evaluated the future growth potential of global Non-Hodgkin Lymphoma (NHL) therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
Browse Related Reports
Global Self-monitoring Blood Glucose Market By Type (Type 1, Type 2, Hyperglycemia ,Hypoglycemia), By Frequency (One, Four, Others), By Product (Glucometer, Software, Test Strips, Lancet), By End-User (Hospital, Personal Care), By Region, Forecast & Opportunities, 2025
https://www.techsciresearch.com/report/self-monitoring-blood-glucose-market/4607.html
Global Portable Ventilator Market, By Type (Invasive Ventilation, Non-Invasive Ventilation), By Mode (Pressure Mode Ventilation; Volume Mode Ventilation; Combined Mode Ventilation), By Application (Aeromedical; Pediatrics; Domiciliary Ventilation; Non-Invasive Ventilation), By End User (Hospital; Ambulance; Clinic; Rehabilitation Center; Others), By Region, Forecast & Opportunities, 2025
https://www.techsciresearch.com/report/portable-ventilator-market/4541.html
Global Oncology Drugs Market By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent), By Route of Administration (Oral, Intravenous, Subcutaneous, Others), By Gender (Male, Female), By Cancer Type (Lung Cancer, Stomach Cancer, Others), By Distribution Channel (Hospital Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2025
https://www.techsciresearch.com/report/oncology-drugs-market/4689.html
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]